Takeda Zejula’s price cut KRW 76,400 → 74,184, 2.9%↓
Eisai’s Equfina film-coated Tab. 50mg (ingredient Safinamide), adjuvant therapy for patients with idiopathic Parkinson’s disease, and Santen’s Eybelis eye drops 0.002% (ingredient: Omidenepag Isopropyl) would be reimbursed from this month.
The insurance coverage will take effect as of February 1, the Ministry of Health and Welfare said.
According to the Ministry, the maximum price for Equfina is set at KRW 1,191 per 50mg. Equfina is adjuvant therapy for levodopa-containing drugs in patients with idiopathic Parkinson’s disease.
The Health Insurance Policy Deliberation Committee evaluated that Equfina meets similar effects compared to alternative drugs and has an insurance coverage adequacy of less than 90% of alternative drugs’ weighted average price.
Santen’s glaucoma treatment Eybelis is priced at KRW 13,628 per 2.5ml bottle.
Eybelis was evaluated that it would be reimbursed if it improves a specific adverse reaction, an iris pigmentation, and its demand is below the weighted average price of alternative drugs.
Meanwhile, among the existing drugs, Takeda’s PARP inhibitor Zejula (ingredient: Niraparib) will cut its price by 2.9% due to extended insurance coverage.
In addition to lowering the price, the coverage of secondary or higher relapsed ovarian cancer maintenance therapy is expanded from adult ovarian cancer patients with existing germline BRCA gene mutations to patients with somatic BRCA mutations.
The coverage is also applied to treat patients with relapsed ovarian cancer with BRCA mutations, who have experience in administering more than 3rd chemotherapy.
